Compare FNWB & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWB | ANIX |
|---|---|---|
| Founded | 1923 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.6M | 103.9M |
| IPO Year | 2012 | 2013 |
| Metric | FNWB | ANIX |
|---|---|---|
| Price | $9.80 | $3.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $14.50 | $9.67 |
| AVG Volume (30 Days) | 28.9K | ★ 181.5K |
| Earning Date | 10-29-2026 | 09-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.00 | 12.82 |
| EPS | ★ N/A | N/A |
| Revenue | $176,000.00 | ★ $210,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.50 | N/A |
| P/E Ratio | $258.25 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.44 | $2.32 |
| 52 Week High | $12.52 | $5.46 |
| Indicator | FNWB | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 44.91 | 53.88 |
| Support Level | $9.50 | $2.51 |
| Resistance Level | $10.30 | $3.46 |
| Average True Range (ATR) | 0.31 | 0.21 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 35.42 | 61.30 |
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It offers various products and services, such as commercial business loans, multi-family real estate loans, auto and consumer loans, transaction accounts, savings and money market accounts, online banking services, etc., focused on the lending, deposit, and money movement needs of individuals, businesses and nonprofit organizations. The Group's operations are mainly focused on serving various communities in Washington State, U.S. Substantially all of its income is derived from a diverse base of commercial, mortgage, and consumer lending activities and investments.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.